Milestone Pharmaceuticals Announces U.S. Availability of CARDAMYST™ (etripamil) Nasal Spray, the First and Only FDA-Approved Self-Administered Treatment for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)

Core Insights - Milestone Pharmaceuticals has launched its first commercial product, CARDAMYST™ (etripamil) nasal spray, for the treatment of paroxysmal supraventricular tachycardia (PSVT) in adults, now available through U.S. retail pharmacies [2][4][8] - The FDA approved CARDAMYST on December 12, 2025, marking the first new treatment for PSVT in over 30 years [6] Product Launch and Support - CARDAMYST will be supported by a patient assistance platform that includes benefits verification, reimbursement support, and copay assistance, with copays capped at $25 for eligible commercially insured patients [3][5] - A national sales force is set to be deployed in mid-February 2026 to promote the product [2][5] Patient Impact and Market Need - Approximately two million people in the U.S. are diagnosed with PSVT, which causes episodes of rapid heartbeats and can significantly impact daily life [7] - The availability of CARDAMYST provides patients with a self-administered treatment option, allowing for on-demand care and greater control over their condition [4][8] Clinical Background - CARDAMYST is a novel calcium channel blocker designed for rapid response therapy, bypassing the need for immediate medical oversight [8] - The product has undergone a robust clinical trial program, including a completed Phase 3 clinical-stage program for PSVT [8]